Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 11/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 7/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.44 |
| ▸ | CDK9 | P50750 | 3/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4246512 | 0.99 | CDK4 (0.53) | CDK4CDK6CDK2KCNH2CDK1 | |
| SCHEMBL13878975 | 0.94 | CDK2 (0.54) | CDK4CDK6CDK2KCNH2CDK1 | |
| SCHEMBL4246906 | 0.93 | CDK2 (0.51) | CDK4CDK6CDK2KCNH2CDK1 | |
| Hydrochloric Acid SCHEMBL4246642 | 0.93 | CDK2 (0.53) | CDK4CDK6CDK2KCNH2CDK1 | |
| SCHEMBL13878974 | 0.93 | CDK2 (0.51) | CDK4CDK6CDK2KCNH2CDK1 | |
| Hydrochloric Acid SCHEMBL4248011 | 0.93 | CDK2 (0.50) | CDK4CDK6CDK2KCNH2CDK1 | |
| SCHEMBL13878979 | 0.92 | CDK4 (0.51) | CDK4CDK6CDK2CDK1CCNE1 | |
| SCHEMBL4252146 | 0.91 | CDK4 (0.52) | CDK4CDK6CDK2KCNH2CDK1 | |
| SCHEMBL13878990 | 0.91 | CDK2 (0.49) | CDK4CDK6CDK2KCNH2CDK1 | |
| Hydrochloric Acid SCHEMBL4250762 | 0.91 | CDK4 (0.51) | CDK4CDK6CDK2CDK1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| US-20230115252-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | UNIVERSITÉ PARIS CITÉ (FR) | 2023-04-13 | — | — | US | disclosed |
| EP-3741375-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-11-25 | — | — | EP | disclosed |
| US-20200323900-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-10-15 | — | — | US | disclosed |
| US-20170209488-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| EP-3169337-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016207366-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016008966-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-01-21 | — | — | WO | disclosed |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | DPYD, TYMS, TYMP | CDK4 746/4885CDK6 184/4885CDK2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.